510(k) Report

510(k) · Cleared

Cleared

My Dose Coach

K163099510(k) TraditionalCleared Mar 22, 2017135-day reviewClass II21 CFR 868.1890

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Sanofi, Inc. · NDC Calculator, Drug Dose

Cleared on Mar 22, 2017 after a 135-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Mar 22, 2017
Review
135 days
Class
Class II
Product code
NDC
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K163099Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in NDC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new NDC device

  1. #1 K242775 InPen System App (MMT-8060 (iOS), MMT-8061…score 18.0 · 10 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All NDC devices

NDC Calculator, Drug Dose: FDA decisions, review times, recalls and adverse event reports over 20 years. 2017, this device’s year, is highlighted.

FDA decisions per year · NDC

2in 2025

2007: 12008: 22010: 12012: 22014: 32015: 32016: 22017: 82018: 32019: 12020: 52021: 32023: 32024: 32025: 22026 (partial year): 4
2007high 8 (2017) · low 0 (2009)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · NDC

60in 2024

2014: 118 days median2015: 199 days median2017: 189 days median2018: 220 days median2020: 53 days median2021: 269 days median2023: 126 days median2024: 60 days median2026 (partial year): 90 days median
2007high 269 (2021) · low 53 (2020)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · NDC

1in 2025

2016: 12017: 22018: 12019: 12022: 12025: 12026 (partial year): 2
2007high 2 (2017) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · NDC

299in 2025

2008: 72009: 42010: 182011: 112012: 22013: 12014: 12015: 12016: 182017: 252018: 212019: 182020: 102021: 112022: 3472023: 4632024: 1682025: 299
2007high 463 (2023) · low 0 (2007)2025

MAUDE reports naming product code NDC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—00
20082—07
20090—04
20101—018
20110—011
20122—02
20130—01
2014311801
2015319901
20162—118
20178189225
20183220121
20191—118
2020553010
20213269011
20220—1347
202331260463
20243600168
20252—1299
20264902—

What is it indicated for?

My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. My Dose Coach is intended as an aid to the patient to provide dose suggestions based upon the HCP’s independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the…

Read the full statement (134 words)

My Dose Coach is indicated for single patient use outside the clinic setting by a previously diagnosed Type 2 Diabetic who has been prescribed a once-daily long-acting basal insulin. My Dose Coach is intended as an aid to the patient to provide dose suggestions based upon the HCP’s independent professional judgment. Before My Dose Coach can be used, the HCP configures the dose instructions for the specific patient and activates the application using the specific patient instructions. The application uses the dose plan instructions provided by the patient’s HCP to provide dose suggestions of once-daily long-acting basal insulin (i.e. basal insulin titration) that are based on the patient’s Fasting Blood Glucose (FBG) as well as hypoglycemia occurrence.

My Dose Coach is not intended to replace the care or advice of a physician or HCP.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K163099: My Dose Coach.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K163099

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026